Axonpen Neuroendoscope Receives 510K Clearance: 1st Post Market Human Trial Commences

January 11, 2021

Axonpen neuroendoscope has received 510K clearance reports ClearMind Biomedical, Inc. Requiring only a narrow channel of 6.5mm through the skull for insertion into the brain, the steerable Axonpen neuroendoscope combines excellent tissue visualization, suction, and irrigation functions.

It has a working channel for use with accessory surgical devices. The Axonpen System is the first neuroendoscope to integrate all these capabilities into one, simple to use, minimally invasive operating platform.

The Axonpen neuroendoscope system supports a clinical shift in the minimally invasive removal of unwanted intracranial fluid and tissue, as commonly manifested in cases of intracerebral hemorrhage (ICH) and subdural hematomas.

One Doctor, One Hour” was the objective driving the ClearMind founders to create the Axonpen neuroendoscope system. Meeting this objective allows a single surgeon to complete some critical surgeries in one hour, even at small-scale regional hospitals. More importantly, access to faster neurosurgical interventions after suffering a hemorrhagic stroke or other fluid producing injury has the potential to improve patient outcomes, including survival.

“Up until the introduction of the Axonpen System, there has been no other integrated neuroevacuation device on the market for minimally invasive neurosurgery,” explains Carrey Yang, ClearMind’s CEO. “Often, expensive and complex equipment is necessary to perform the surgery, requiring that patients be transferred to a large medical center, delaying the moment surgery can begin.”

Yang also pointed out examples where the Axonpen may provide benefit: “The most critical period in treating ICH is the first 24 hours, underscoring the importance of swift and effective emergency treatment.”  He went on to comment that apart from the speediness of treatment, the Axonpen’s low rebleeding risk is an equally important advantage.

The first post-market human trial of the Axonpen has commenced. The trial, which will consist of 30 subjects, is focused on procedural safety and generating the correlation between the use of the Axonpen System and functional independence measures. US human trials are planned for the 3rd quarter of 2021.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”